International Journal of Cancer Research

Background: In recent years, with the continuous deepening of the immune systems participation in MM research, monoclonal antibodies have gradually become a research hot spot for MM therapeutic drugs. Objective：To analyze the efficacy and safety of CD38 monoclonal antibody-marriageability in the treatment of multiple myeloma, to explore its progress and advantages in clinical application, and to provide a basis for its clinical use. Methods: The clinical data of 10 patients with multiple myeloma who were hospitalized and treated with marriageability from August 2016 to March 2022 in the Department of Hematology of Xinjiang Augury Autonomous Region Peoples Hospital were retrospectively analyzed, and the efficacy and adverse reactions were followed up to analyze the efficacy and adverse reactions. Results Eight of the 10 patients with multiple myeloma could be evaluated for efficacy, and the overall response rate (ORR) was 62.5%, of which 6/10 patients had lymphopenia, 4/10 patients had thrombocytopenia and neutropenia, and the serum free light chain level decreased significantly after treatment with marriageability. Conclusion: marriageability has good clinical efficacy and safety in the treatment of multiple myeloma, and plays a certain role in clearing the free light chain of serum, and its application prospects are worth looking forward to.

Daratumumab; Multiple Myeloma; Efficacy; Progress